Literature DB >> 4226381

African horse-sickness killed-virus tissue culture vaccine.

Y Ozawa, S Bahrami.   

Abstract

Formalized African horse-sickness (AHS) type 9 virus cultivated in monkey kidney stable (MS) cell cultures was experimentally used for immunizing horses. Inactivated vaccines prepared either from viscerotropic or neurotropic type 9 AHS virus produced antibodies in vaccinated horses. Immunity developed in all horses vaccinated with various amounts of the vaccine, and protected them from infection, when challenged 5 weeks after vaccination.

Entities:  

Mesh:

Substances:

Year:  1966        PMID: 4226381      PMCID: PMC1494603     

Source DB:  PubMed          Journal:  Can J Comp Med Vet Sci        ISSN: 0316-5957


  1 in total

1.  SEROLOGIC STUDIES OF AFRICAN HORSE-SICKNESS VIRUS WITH EMPHASIS ON NEUTRALIZATION TEST IN TISSUE CULTURE.

Authors:  A HAZRATI; Y OZAWA
Journal:  Can J Comp Med Vet Sci       Date:  1965-07
  1 in total
  4 in total

1.  Inactivated African horse sickness virus cell culture vaccine.

Authors:  H Mirchamsy; H Taslimi
Journal:  Immunology       Date:  1968-01       Impact factor: 7.397

2.  Immunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virus.

Authors:  Yuta Kanai; Piet A van Rijn; Mieke Maris-Veldhuis; Yuki Kaname; T N Athmaram; Polly Roy
Journal:  Vaccine       Date:  2014-07-18       Impact factor: 3.641

3.  Re-parameterization of a mathematical model of African horse sickness virus using data from a systematic literature search.

Authors:  Emma L Fairbanks; Marnie L Brennan; Peter P C Mertens; Michael J Tildesley; Janet M Daly
Journal:  Transbound Emerg Dis       Date:  2022-01-12       Impact factor: 4.521

4.  Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge.

Authors:  Berta Alberca; Katarzyna Bachanek-Bankowska; Marta Cabana; Eva Calvo-Pinilla; Elisenda Viaplana; Lorraine Frost; Simon Gubbins; Alicia Urniza; Peter Mertens; Javier Castillo-Olivares
Journal:  Vaccine       Date:  2014-05-14       Impact factor: 3.641

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.